Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS707035是一种 HIV-1 整合酶抑制剂,IC50为15 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 433 | 现货 | ||
2 mg | ¥ 629 | 现货 | ||
5 mg | ¥ 997 | 现货 | ||
10 mg | ¥ 1,730 | 现货 | ||
25 mg | ¥ 2,930 | 现货 | ||
50 mg | ¥ 4,350 | 现货 | ||
100 mg | ¥ 6,180 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,150 | 现货 |
产品描述 | BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. Phase 2. |
靶点活性 | HIV-I integrase:15 nM |
体外活性 | BMS-707035 is a pyrimidine carboxamide similar to Raltegravir, the first integrase inhibitor licensed for clinical use. BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity with IC50 of 15 nM. [1] However, several IN mutations, including V75I, Q148R, V151I, and G163R are found to confer resistance to HIV IN inhibitors. The binding of BMS-707035 and target DNA to IN are mutually exclusive events, as revealed by the fact that the inhibition of strand transfer catalysis by BMS-707035 is overcome by increasing amount of target DNA. The binding affinity of BMS-707035 to IN is also affected by the four terminal bases at the 5' end of the pre-processed U5 long terminal repeat (LTR). Gln148 of IN is crucial for the binding of BMS-707035 to IN. [1] The 3' terminus of the viral LTR, on the other hand, retards the rate of BMS-707035 association with IN, by regulating the kinetics of binding and dissociation. [2] |
别名 | N-[(4-氟苯基)甲基1,6-二氢-5-羟基-1-甲基-6-氧代-2-(四氢-1,1-二氧-2H-1,2-噻嗪-2-基)-4-嘧啶甲酰胺 |
分子量 | 410.42 |
分子式 | C17H19FN4O5S |
CAS No. | 729607-74-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 36 mg/mL (87.7 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4365 mL | 12.1826 mL | 24.3653 mL | 60.9132 mL |
5 mM | 0.4873 mL | 2.4365 mL | 4.8731 mL | 12.1826 mL | |
10 mM | 0.2437 mL | 1.2183 mL | 2.4365 mL | 6.0913 mL | |
20 mM | 0.1218 mL | 0.6091 mL | 1.2183 mL | 3.0457 mL | |
50 mM | 0.0487 mL | 0.2437 mL | 0.4873 mL | 1.2183 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BMS-707035 729607-74-3 Microbiology/Virology Proteases/Proteasome HIV Protease HIV-1 integrase strand transfer HIV Human immunodeficiency virus antiviral phamacokinetics HIV Integrase BMS 707035 CYP inhibit strand transfer N-[(4-氟苯基)甲基1,6-二氢-5-羟基-1-甲基-6-氧代-2-(四氢-1,1-二氧-2H-1,2-噻嗪-2-基)-4-嘧啶甲酰胺 Inhibitor BMS707035 inhibitor